Abstract:AIDS Research and Human RetrovirusesVol. 30, No. S1 Novel Vaccine ConceptsFree AccessLive Adenovirus Type 4 Recombinants Induce Durable Neutralizing Antibody Responses to Influenza H5 with High Levels of Somatic Hypermutation in HumansJinghe Huang, Byong Kang, Adam Wheatley, Sandeep Narpala, Adrian Mcdermott, April Poole, Robert Bailer, Richard Koup, Stephen Migueles, Marc Gurwith, and Mark ConnorsJinghe HuangNIAID/LIR, HIV-Specific Immunity Section, Bethesda, MD, United StatesSearch for more papers by this author, Byong KangNIAID/LIR, HIV-Specific Immunity Section, Bethesda, MD, United StatesSearch for more papers by this author, Adam WheatleyNIAID, NIH, Vaccine Research Center, Bethesda, MD, United StatesSearch for more papers by this author, Sandeep NarpalaNIAID, NIH, Vaccine Research Center, Bethesda, MD, United StatesSearch for more papers by this author, Adrian McdermottNIAID, NIH, Vaccine Research Center, Bethesda, MD, United StatesSearch for more papers by this author, April PooleNIAID/LIR, HIV-Specific Immunity Section, Bethesda, MD, United StatesSearch for more papers by this author, Robert BailerNIAID, NIH, Vaccine Research Center, Bethesda, MD, United StatesSearch for more papers by this author, Richard KoupNIAID, NIH, Vaccine Research Center, Bethesda, MD, United StatesSearch for more papers by this author, Stephen MiguelesNIAID/LIR, HIV-Specific Immunity Section, Bethesda, MD, United StatesSearch for more papers by this author, Marc GurwithPaxVax Inc., La Jolla, CA, United StatesSearch for more papers by this author, and Mark ConnorsNIAID/LIR, HIV-Specific Immunity Section, Bethesda, MD, United StatesSearch for more papers by this authorPublished Online:30 Oct 2014https://doi.org/10.1089/aid.2014.5073.abstractAboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail OA16.01Background: Induction of durable antibody responses capable of neutralizing diverse HIV-1 isolates is the most important goal in HIV vaccinology. Broad and potent HIV Env-specific antibodies isolated from humans are characterized by binding to conserved sites on Env and by high levels of hypermutation. Live virus recombinant vectors may provide prolonged exposure to transgene-encoded antigen and may more potently drive affinity maturation than non-replicating vectors. We report results of a small Phase 1 trial of mucosal immunization with live adenovirus type 4 encoding influenza H5 HA (Ad4-H5-Vtn) as a model antigen. We explored its ability to induce durable, broad neutralizing antibody responses through upper respiratory tract application.Methods: Live Ad4-H5Vtn (103-108 viral particles (VP)) was administered by tonsillar swab or by nasal spray in a dose escalation study. Controls received (1010 VP) as enteric-coated capsules. Neutralizing antibodies were measured by a pseudotype HA lentiviral vector system. B cells were isolated using fluorescent HA probes. Immunoglobulin genes were cloned for mutation analysis, and re-expressed to measure neutralization potency and breadth.Results: The vaccine was well tolerated and symptoms were consistent with mild URI. Tonsillar and nasal immunizations were the most immunogenic routes inducing neutralizing antibody responses at day 60 (ID50=809 and 666 respectively) which rose during the first 6 months. B cells that expanded early were specific for both H1 and H5 and were directed to the conserved stalk, with H5 HA-monospecific cells expanding by 6 months. The median level of hypermutation was 3.6% compared to germline at week 4 and 7.4% at weeks 34–52. However, some antibodies contained 13–34% mutation and neutralized group 1 and 2 viruses.Conclusions: A single dose of live recombinant Ad4-H5 can induce highly mutated antibodies, suggesting that mucosal administration is a promising platform for the induction of HIV-specific neutralizing antibodies.FiguresReferencesRelatedDetails Volume 30Issue S1Oct 2014 InformationCopyright 2014, Mary Ann Liebert, Inc.To cite this article:Jinghe Huang, Byong Kang, Adam Wheatley, Sandeep Narpala, Adrian Mcdermott, April Poole, Robert Bailer, Richard Koup, Stephen Migueles, Marc Gurwith, and Mark Connors.Live Adenovirus Type 4 Recombinants Induce Durable Neutralizing Antibody Responses to Influenza H5 with High Levels of Somatic Hypermutation in Humans.AIDS Research and Human Retroviruses.Oct 2014.A44-A44.http://doi.org/10.1089/aid.2014.5073.abstractPublished in Volume: 30 Issue S1: October 30, 2014PDF download

[Anti-Adenovirus Neutralizing Antibodies and Gag-specific Cellular Immune Responses in Macaca Fascicularis Immunized with Ad5-HIVgag].

[Comparison of the Immnunogenicity of Raav2/1 and Rad5 Rad5 Expressing HIV-1 Gag].

[Immunogenicity of Recombinant Adeno-Asscociated Virus Type 1 Expressing HIV-1 Gp120 Gene in Mice and Rhesus Macaques].

A Mucosal Adenovirus Prime/Systemic Envelope Boost Vaccine Regimen Elicits Responses in Cervicovaginal and Alveolar Macrophages of Rhesus Macaques Associated With Delayed SIV Acquisition and B Cell Help

[Immune Response Induced by HIV DNA Vaccine Combined with Recombinant Adeno-Associated Virus].

Circumventing Antivector Immunity by Using Adenovirus-Infected Blood Cells for Repeated Application of Adenovirus-Vectored Vaccines: Proof of Concept in Rhesus Macaques

Neutralizing monoclonal antibodies protect against human adenovirus type 55 infection in transgenic mice and tree shrews

[Study on the Immunogenicity of HIV-1 Gag Vaccine].

[Immune Responses in Rhesus Induced by Recombinant Adenovirus Ad-LMP2].

Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques.

Live Adenovirus Type 4 Recombinants Induce Durable Neutralizing Antibody Responses to Influenza H5 with High Levels of Somatic Hypermutation in Humans

Gag-Specific Cytotoxic T-Lymphocyte-Based Control of Primary Simian Immunodeficiency Virus Replication in a Vaccine Trial

Gag-specific Cellular Immunity Determines in Vitro Viral Inhibition and in Vivo Virologic Control Following SIV Challenges of Vaccinated Monkeys

Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.

Enhancement of Primary and Secondary Cellular Immune Responses Against Human Immunodeficiency Virus Type 1 Gag by Using DNA Expression Vectors That Target Gag Antigen to the Secretory Pathway

Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques

Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus.

Sequential Immunization of Macaques with Two Differentially Attenuated Vaccines Induced Long-Term Virus-Specific Immune Responses and Conferred Protection against AIDS Caused by Heterologous Simian Human Immunodeficiency Virus (SHIV89.6P)

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIVmac251

[The Immune Response in Mice Inoculated with HIV-1 Gag-Gp120 Chimeric Gene DNA Vaccine and IL-18 Plasmid].